BR9712957A - Vìrus a adenovìrus recombinantes defeituosos, plasmìdeos procariótico e bifuncional, célula procariótica, utilização de um vìrus recombinante defeitusos, e, composição farmacêutica - Google Patents

Vìrus a adenovìrus recombinantes defeituosos, plasmìdeos procariótico e bifuncional, célula procariótica, utilização de um vìrus recombinante defeitusos, e, composição farmacêutica

Info

Publication number
BR9712957A
BR9712957A BR9712957-7A BR9712957A BR9712957A BR 9712957 A BR9712957 A BR 9712957A BR 9712957 A BR9712957 A BR 9712957A BR 9712957 A BR9712957 A BR 9712957A
Authority
BR
Brazil
Prior art keywords
defective recombinant
prokaryotic
recombinant virus
adenoviruses
pharmaceutical composition
Prior art date
Application number
BR9712957-7A
Other languages
English (en)
Inventor
Patrick Benoit
Sandrine Seguret
Nicolas Duverger
Didier Ouy
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of BR9712957A publication Critical patent/BR9712957A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"VìRUS E ADENOVìRUS RECOMBINANTES DEFEITUOSOS, PLASMìDEOS PROCARIóTICO E BIFUNCIONAL, CéLULA PROCARIóTICA, UTILIZAçãO DE UM VìRUS RECOMBINANTE DEFEITUOSO, E, COMPOSIçãO FARMACêUTICA". A presente invenção refere-se a um vírus recombinante defeituoso e de preferência a um adenovírus caracaterizado pelo fato de que ele compreende pelo menos dois ácidos nucleicos que codificam para enzimas, proteínas e/ou co-fatores distintos e implicados no nível de transporte inverso do colesterol, os ditos ácidos nucleicos estando ligados operacionalmente a um promotor transcricional e separados um do outro por uma seq³ência que codifica para um sítio de entrada interna do ribossoma IRES. Ela se refere também a construções plasmídicas úteis para preparar estes adenovírus, a célula transformadas por estes plasmídeos ou adenovírus e a composições farmacêuticas que contenham dos ditos adenovírus.
BR9712957-7A 1996-11-15 1997-11-13 Vìrus a adenovìrus recombinantes defeituosos, plasmìdeos procariótico e bifuncional, célula procariótica, utilização de um vìrus recombinante defeitusos, e, composição farmacêutica BR9712957A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9613969A FR2755975B1 (fr) 1996-11-15 1996-11-15 Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
PCT/FR1997/002043 WO1998022606A1 (fr) 1996-11-15 1997-11-13 Adenovirus recombinants bicistroniques pour le traitement de pathologies liees aux dyslipoproteinemies

Publications (1)

Publication Number Publication Date
BR9712957A true BR9712957A (pt) 2000-02-01

Family

ID=9497670

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712957-7A BR9712957A (pt) 1996-11-15 1997-11-13 Vìrus a adenovìrus recombinantes defeituosos, plasmìdeos procariótico e bifuncional, célula procariótica, utilização de um vìrus recombinante defeitusos, e, composição farmacêutica

Country Status (14)

Country Link
EP (1) EP0941355A1 (pt)
JP (1) JP2001506488A (pt)
KR (1) KR20000053320A (pt)
AU (1) AU721654B2 (pt)
BR (1) BR9712957A (pt)
CA (1) CA2271437A1 (pt)
CZ (1) CZ170399A3 (pt)
FR (1) FR2755975B1 (pt)
HU (1) HUP9904500A3 (pt)
IL (1) IL129823A0 (pt)
NO (1) NO992260L (pt)
SK (1) SK63499A3 (pt)
WO (1) WO1998022606A1 (pt)
ZA (1) ZA9710271B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047690A2 (en) * 1998-03-16 1999-09-23 Introgen Therapeutics, Inc. Multigene vectors
DE10039844A1 (de) * 1999-08-10 2001-04-19 Hepavec Ag Fuer Gentherapie Kombinationsvektoren für den Gentransfer, Verfahren zu ihrer Herstellung und ihre Verwendung
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
CA2404235C (en) * 2000-03-24 2010-09-21 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US6544780B1 (en) * 2000-06-02 2003-04-08 Genphar, Inc. Adenovirus vector with multiple expression cassettes
US7208322B2 (en) 2001-04-02 2007-04-24 Agilent Technologies, Inc. Sensor surfaces for detecting analytes
US9976171B2 (en) * 2011-08-08 2018-05-22 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
WO2021031551A1 (zh) 2019-08-19 2021-02-25 南京诺惟生物科技有限公司 一种调控脂质代谢的复制型溶瘤腺病毒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003143A1 (en) * 1991-08-07 1993-02-18 Anderson W French Retroviral vectors containing internal ribosome entry sites
GB9125896D0 (en) * 1991-12-05 1992-02-05 Almond Jeffrey W Bicistronic viruses
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
PT787200E (pt) * 1994-10-28 2005-08-31 Univ Pennsylvania Adenovirus melhorado e metodos para a sua utilizacao
FR2731710B1 (fr) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique

Also Published As

Publication number Publication date
HUP9904500A3 (en) 2002-01-28
FR2755975B1 (fr) 1999-05-07
WO1998022606A1 (fr) 1998-05-28
CA2271437A1 (fr) 1998-05-28
AU721654B2 (en) 2000-07-13
NO992260D0 (no) 1999-05-10
AU5125298A (en) 1998-06-10
ZA9710271B (en) 1998-08-21
KR20000053320A (ko) 2000-08-25
JP2001506488A (ja) 2001-05-22
SK63499A3 (en) 2000-05-16
IL129823A0 (en) 2000-02-29
FR2755975A1 (fr) 1998-05-22
CZ170399A3 (cs) 1999-08-11
HUP9904500A2 (hu) 2000-05-28
EP0941355A1 (fr) 1999-09-15
NO992260L (no) 1999-05-10

Similar Documents

Publication Publication Date Title
Wilkinson Troponin C from rabbit slow skeletal and cardiac muscle is the product of a single gene
Yamauchi et al. Purification and characterization of a 3, 5, 3'-L-triiodothyronine-specific binding protein from bullfrog tadpole plasma: a homolog of mammalian transthyretin
HK1047755A1 (zh) 胰島素樣生長因子激動肽的用途
BR9712957A (pt) Vìrus a adenovìrus recombinantes defeituosos, plasmìdeos procariótico e bifuncional, célula procariótica, utilização de um vìrus recombinante defeitusos, e, composição farmacêutica
FI941474A0 (fi) Seos nukleiinihappo-kompleksien viemiseksi korkeampiin eukaryoottisiin soluihin
RU2001117230A (ru) Пептиды, ингибирующие трансформирующий фактор роста tgf$$$1
ATE378407T1 (de) Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
EE9900611A (et) Osteoprotegeriini siduvad valgud ja retseptorid
Liu et al. Molecular mechanism for cooperation between Sp1 and steroidogenic factor-1 (SF-1) to regulate bovine CYP11A gene expression
EE9900313A (et) Interferooni stabiilsed vedelformulatsioonid
ATE364083T1 (de) Immunogene zusammensetzungen gegen eine helicobacterinfektion, verwendung von polypeptiden in diesen zusammensetzungen und nukleinsäurendie besagte polypeptide kodieren
Ueno Local structural changes in tropomyosin detected by a trypsin-probe method
Head et al. Affinity-chromatographic isolation and some properties of troponin C from different muscle types
Larochelle et al. Efficient muscle-specific transgene expression after adenovirus-mediated gene transfer in mice using a 1.35 kb muscle creatine kinase promoter/enhancer
Rupp et al. Chicken liver TGGCA protein purified by preparative mobility shift electrophoresis (PMSE) shows a 36.8 to 29.8 kd microheterogeneity
DE59814354D1 (de) Zellvolumenregulierte humane Kinase h-sgk
Fawell et al. Androgen-regulated proteins of rat seminal vesicle secretion constitute a structurally related family present in the copulatory plug
HUT43188A (en) Monoclonic antibodies and antigenes for treatment of human, having not-small celts carcinoma of lungs
Evans et al. The resolution of Ascaris cuticle collagen into three chain types
WO1997007135A3 (en) Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
DK0594771T3 (da) Cycloheximidresistens i nukleotidsekvenser og -proteiner
Hoff et al. Characterization of the factor E1BF from a rat hepatoma that modulates ribosomal RNA gene transcription and its relationship to the human Ku autoantigen
Kurihara et al. Chemical, immunological and catalytic properties of 2': 3'-cyclic nucleotide 3'-phosphodiesterase purified from brain white matter.
KNAZEK et al. Growth hormone causes rapid induction of lactogenic receptor activity in the Snell dwarf mouse liver
Ui Electrophoretic mobility and isoelectric point of hog thyroglobulin

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]